SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S.
EuBiologics announced Friday that its proprietary adjuvant platform EcML has completed Type IV Drug Master File registration with the US Food and Drug Administration and received an official DMF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results